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Abstract: Both nitroreductase and transglutaminase activities have been assayed in the I0 000 × g supernatant fluids of rat intestine 
homogenates after Triton X-100 treatment. Incubation of '*C-nitrofurantoin in the intestine extract yielded protein-bound 14C-labeled 
products. Injection into rabbits of the conjugated protein similarly prepared with unlabeled nitrofurantoin elicited formation of anti- 
bodies against nitrofurantoin. These results suggest that intestinal metabolism and conjugation to protein of orally administered drugs 
may serve as a probable mechanism of drug allergy, and this may be accomplished by enzymatic coupling of relatively stable drug 
metabolites to protein carriers. 
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Introduction 
Landsteiner's (1936) classical immunochemical 
studies demonstrated that low molecular weight 
compounds (which include most drugs) generally 
must be covalently bound to a high molecular 
weight carrier in order to stimulate an anti-hapten 
antibody response. Eisen (1959) additionally 
showed that the sensitizing capacity of simple or- 
ganic molecules also correlated with their capacity 
to react with proteins in vivo. Conversely, the re- 
versible, ionic and hydrophobic interactions of 
many drugs with albumin and other serum proteins 
are insufficient to generate an immune response 
(Parker, 1979). An alternative possibility is that sta- 
ble drugs or drug metabolites gain antigenicity by 
being covalently linked to high molecular weight 
carriers by enzymes normally present in various tis- 
sues. This has been documented by the capacity of 
transglutaminases to couple isoniazid and hydral- 
azine to protein (Lorand et al., 1972; Buxman, 
1979). 
Although the evidence is largely circumstantial, 
it is likely that the generation of immunogenic drug 
hapten-protein conjugates most often occurs in the 
liver: it is the site of metabolism of many drugs, it 
is a source of several types of enzymes potentially 
capable of binding drug metabolites to proteins, 
and it is the frequent target of drug reactions which 
appear to have an allergic basis (as well as toxic 
reactions) (Parker 1980). However, a more com- 
plete understanding of pathogenetic mechanisms of 
drug allergy needs to take into account the possible 
generation of drug-related immunogenicity in other 
organs. Since most drugs are administered orally, 
the gastrointestinal tract mucosa in particular war- 
rants assessments in this respect. For this purpose 
we choose to study its possible capacity to confer 
antigenicity on nitrofurantoin, because this drug 
commonly causes adverse reactions which may be 
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immunologically mediated (Holmberg et al., 1980), 
and its metabolism has been studied (Hoener and 
Krueger, 1984; Moreno et al., 1984). The objective 
was to show whether rat intestinal walls contained 
enzymes that could not only reduce nitrofurantoin 
but also conjugate the reduction product(s) to pro- 
tein and to determine whether the protein conjugate 
so formed was immunogenic with respect to the 
hapten. 
Materials and Methods 
Liver and intestinal walls of male adult rats of the 
Sprague-Dawley strain were used. Intestinal walls 
were prepared by removing mesenteries, cutting the 
walls lengthwise and rinsing in fresh portions of 
ice-cold 0.15 M KC1 to wash away intestinal con- 
tents as much as possible. The tissues were blotted 
on filter paper before weighing. Tissue homoge- 
nates were made in ice-cold 0.15 M KC1 containing 
0.1% Triton X-100 and centrifuged at 10 000 × g 
for 25 min at 4°C. The supernatant fluids were used 
for the experiments described below. Male New 
Zealand white rabbits were used for immunization. 
[14C-Methylene]-nitrofurantoin (specific activity 
11.3 #Ci/mg) was a gift from Norwich-Eaton Phar- 
maceuticals (Norwich, NY). Goat anti-rabbit im- 
munoglobulin serum was purchased from Bio-Rad. 
All other chemicals were of reagent grade. 
Nitroreductase assay 
The incubation mixture (Aufrere et al., 1978) con- 
tained 25 mM potassium phosphate buffer, pH 7.4, 
3.8 mM glucose-6-phosphate, 0.67 mM MgCI2, 
0.16 mM nitrofurantoin, 0.12 mM NADP +, and 
tissue extract containing about 20 mg tissue in a 
final volume of 1 ml. Glucose-6-phosphate and 
NADP ÷ were used to generate NADPH by glu- 
cose-6-phosphate dehydrogenase present in the tis- 
sue extract. NADPH was the actual reducing agent 
in the reduction. The mixture, in a small bottle 
capped with a perforable rubber stopper, was 
flushed with nitrogen for 2-3 min to assure anaer- 
obic conditions. It was then incubated at 37°C for 
0 (as control) and 20 min. At the end of incubation, 
an aliquot of the reaction mixture was used for de- 
termining the amount of nitrofurantoin remaining. 
The decrease in nitrofurantoin from nitroreduc- 
tion was measured by a modification of the hy- 
amine assay (Mattok et al., 1970). 0.5 ml of the 
reaction mixture was extracted with 1.25 ml of ni- 
tromethane and centrifuged at 1000 × g for 15 min. 
The aqueous layer was discarded. An aliquot of 830 
#1 of the nitromethane layer was mixed with 83 #1 
of 3.3 mM hyamine hydroxide. The absorbance at 
400 nm was measured 5 rain after the hyamine ad- 
dition. The amount of nitrofurantoin remaining in 
the reaction mixture was estimated by means of a 
standard curve of nitrofurantoin following nitro- 
methane extraction. 
Transglutaminase assay 
This assay was done with the procedure of Con- 
nellan et al. (1971). The reaction mixture contained 
0.1 M Tris-acetate buffer, pH 6.0, 5 mM CaC12, 100 
mM hydroxylamine hydrochloride, 10 mM gluta- 
thione, 30 mM carbobenzoxy(CBZ)-L-glutaminyl- 
glycine, and tissue extract containing about 50 mg 
tissue in a final volume of 1 ml. Incubation was 
done at 37°C for 20 min. The control contained no 
CBZ-L-glutaminylglycine. At the end of incubation, 
0.12 ml of a ferric chloride reagent (Wu, 1964) was 
added. The mixture was centrifuged at 1000 × g 
for 10 min. The supernatant fluid was read at 525 
nm. In some experiments, 100 /~M iodoacetamide 
was added to the reaction mixture to see if the en- 
zyme activity in rat intestine would be inhibited as 
in guinea pig liver (Folk and Cole, 1966). 
Protein was determined according to the proce- 
dure of Lowry et al. (1951) with bovine serum al- 
bumin as standard. 
Binding of nitrofurantoin metabolite to protein 
These experiments were done first with 14C-nitro- 
furantoin under anaerobic conditions. The incu- 
bation mixture consisted of the same components 
as used in both nitroreductase and transglutami- 
nase assays, except that hydroxylamine and CBZ- 
L-glutaminylglycine were omitted, the final pH 
being 7.2. These components were 0.16 mM nitro- 
furantoin, 3.8 mM glucose-6-phosphate, 0.67 mM 
MgCI2, 0.12 mM NADP +, 5 mM CaCI2, 10 mM 
glutathione, 25 mM potassium phosphate buffer, 
pH 7.4, and tissue extract containing 3.0-21.0 mg 
protein per ml of the reaction mixture. In addition, 
4 mg bovine serum albumin was added per ml of 
reaction mixture to assure that sufficient protein 
would be available for coupling to drug metab- 
olites, and the initial radioactivity in the reaction 
mixture was adjusted to about 45 000 cpm/ml. In- 
cubation was done at 370C for 30 rain. At the end 
of incubation, trichloroacetic acid was added to a 
final concentration of 10%. The precipitate was 
washed repeatedly with 3% trichloroacetic acid un- 
til the washings contained no significant radioactiv- 
ity above the background. The precipitate was dis- 
solved in 1 N NaOH for counting in a Packard 
liquid scintillation spectrometer (45% counting ef- 
ficiency). Incubation mixtures with extract inacti- 
vated for 20-30 rain at 500C served as controls. In 
a second series of experiments, protein-bound ni- 
trofurantoin metabolite was prepared with unla- 
beled nitrofurantoin. After the trichloroacetic acid 
precipitate was dissolved in NaOH, the protein so- 
lution was dialyzed against saline, concentrated if 
necessary, and used for immunization. 
Immunization of rabbits 
The protein conjugate of nitrofurantoin metabolite 
prepared with rat small intestine extract was used 
to immunize 2 rabbits. A concentrate of the con- 
jugate was mixed with Freund's complete adjuvant 
and injected intradermally at multiple sites on the 
back of the animals. One month later, a booster 
injection in Freund's incomplete adjuvant was giv- 
en similarly. The initial and booster injections each 
contained the equivalent of 50/tg of bound nitro- 
furantoin. 
Radioimmunoassay 
The assay was carried out as follows: 245 /A of 
phosphate buffered saline (0.14 M NaC1, 0.01 M 
phosphate buffer, pH 7.2, 0.02% sodium azide, and 
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1% bovine serum albumin) containing about 4000 
cpm of 14C-nitrofurantoin in 1.2 nmol was incu- 
bated with 5 pl of rabbit serum (control or immu- 
nized) for 2 h at 4°C. When necessary, serum sam- 
ples from immunized animals were diluted with 
control serum. After the incubation, 350 pl of phos- 
phate buffered saline containing 100 #1 of goat an- 
tirabbit immunoglobulin serum titered to the equiv- 
alence point was added, mixed and kept at 4°C for 
18 h. The mixture was centrifuged at 2000 x g for 
10 min, and 500 pl of the supernatant fluid was used 
for counting. 
Results and Discussion 
Table I shows the results of the tests for nitrored- 
uctase activity in rat liver and small intestine. The 
activity was higher in the liver than in the small 
intestine. Aerobic conditions inhibited greatly the 
reductase activity. Since Batteli et al. (1972) have 
reported that rat small intestine contained higher 
activity of xanthine oxidase than other rat tissues, 
we used hypoxanthine as cofactor to measure ni- 
troreductase activity in small intestine and obtained 
similar results to those with NADPH. Hence, ni- 
trofurantoin was also a substrate of xanthine oxi- 
dase in small intestine as it was in liver (Boyd et al., 
1979; Wang et al., 1974). 
As mentioned above, transglutaminase activity 
has been shown to be involved in the transfer of 
some drugs, such as hydralazine, to protein as a 
mechanism for drug allergy. Certain hydroxylam- 
ines can also serve as substrates of transglutami- 
nase, and this reaction has been utilized in the 
colorimetric assay of the enzyme activity. Table II 
shows the enzyme activity in small intestine and 
cecum as compared with that in liver. The latter 
had activity 10-15 times higher than the intestines, 
but the intestinal activity was significant and also 
susceptible to iodoacetamide inhibition, as is the 
liver enzyme. 
We then proceeded to study binding of nitrofur- 
antoin metabolite to protein in preparation of the 
complex for subsequent immunization. Essentially, 
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TABLE I 
Nitroreductase activity in rat liver and small intestine 
Extract Cofactor Conditions a Activity b 
(nmol/mg protein/min) 
Liver NADPH Anaerobic 2.7 4- 0.2 
Aerobic 0.46 4- 0.12 
Small intestine NADPH Anaerobic 2.0 4, 0.1 
Aerobic 0.32 4- 0.07 
Hypoxanthine Anaerobic 1.8 4- 0.2 
a The reaction mixture contained 0.16 mM nitrofurantoin, 0.67 mM MgCI2, 3.8 mM glucose-6-phosphate, 0.12 mM NADP +, 25 mM 
potassium phosphate buffer, pH 7.4, and about 20 mg tissue per ml. When hypoxanthine (0.20 mM) was used, glucose-6-phosphate 
and NADP + were omitted. Incubation was done under N2 or air at 37°C for 20 min. 
b Assessed by the decrease in nitrofurantoin present as measured by a modification of the hyamine assay of Mattok et al. (1970). 
the  c o n d i t i o n s  fo r  a s say ing  n i t r o r e d u c t a s e  a n d  
t r a n s g l u t a m i n a s e  ac t iv i t ies  were  c o m b i n e d .  S ince  
the  p r e p a r a t i o n  o f  the  h ighes t  y ie ld  o f  the  c o m p l e x  
r a t h e r  t h a n  the  m e a s u r e m e n t  o f  in i t ia l  ra tes  o f  the  
r eac t i ons  was  o u r  goa l ,  we  a l l o w e d  the  i n c u b a t i o n  
to  p r o c e e d  fo r  a l o n g e r  p e r i o d  o f  t ime  t h a n  d i c t a t e d  
by the  in i t ia l  r a te  m e a s u r e m e n t .  T h e  resul t s  o f  sev- 
e ra l  e x p e r i m e n t s  w i th  1 4 C - n i t r o f u r a n t o i n  a re  
s u m m a r i z e d  in T a b l e  I I I .  I n c r e a s i n g  the  p r o t e i n  
c o n c e n t r a t i o n  in the  r e a c t i o n  m i x t u r e  i n c r e a s e d  
p r o p o r t i o n a l l y  the  level  o f  b o u n d  r a d i o a c t i v i t y  so 
TABLE II 
Transglutaminase activity in rat liver and intestines a 
Extract Iodoacetamide Activity 
(100 #M) (nmol/mg 
protein/min) 
Liver - 35 :t: 3.0 
+ 0.72 4. 0.04 
Small intestine - 2.5 4, 0.3 
+ 0.10 4, 0.01 
Cecum - 3.7 4, 0.2 
+ 0.13 4. 0.01 
The reaction mixture contained 5 mM CaCI2, 100 mM hy- 
droxylamine hydrochloride, 10 mM glutathione, 30 mM 
CBZ-L-glutaminylglycine, 0.1 M Tris acetate buffer, pH 6.0, 
and about 50 mg tissue per ml. Incubation was done at 37°C 
for 20 min. 
t h a t  the  level  o f  r a d i o a c t i v i t y  b o u n d  per  m g  p r o t e i n  
r e m a i n e d  nea r ly  c o n s t a n t ,  sugges t ing  tha t  the  b ind-  
ing  t akes  p l ace  a t  specific,  s a t u r a b l e  sites o f  the  p r o -  
tein.  T h e  a v e r a g e  was  50 n m o l  o f  the  l abe led  m e t a b -  
ol i te  b o u n d  pe r  m g  p ro te in .  W h e n  pa ra l l e l  exper i -  
m e n t s  w i t h  u n l a b e l e d  n i t r o f u r a n t o i n  were  d o n e ,  we 
a s s u m e d  a s imi la r  level  o f  b i n d i n g  h a d  o c c u r r e d ,  
TABLE III 
Binding of nitrofurantoin metabolite to protein in rat small in- 
testine" 
Experiment Protein in 14C-Nitro- 14C- 
number reaction furantoin Metabolite 
mixture in reaction bound to 
(mg/ml) mixture protein b 
(cpm/ml) (nmol/mg) 
1 7.5 37 240 51 
2 15.5 43 500 54 
3 12.7 42 730 42 
4 22.3 49 480 54 
a The reaction mixture contained 0.16 mM nitrofurantoin with 
radioactivity adjusted to 35 000-50 000 cpm/ml, 3.8 mM glu- 
cose-6-phosphate, 0.67 mM MgCI2, 0.12 mM NADP ÷, 5 mM 
CaClz, 10 mM glutathione, 25 mM potassium phosphate buf- 
fer, pH 7.4, bovine serum albumin 4 mg/ml, and tissue extract 
containing 3.0-18.0 mg protein per ml. Each experiment was 
run for 30 min in duplicate. Deviations from the respective 
means were less than 10%, 
b Measured on the repeatedly washed trichloroacetic acid pre- 
cipitate redissolved in NaOH. 
and 50 nmol/mg protein was used for calculating 
the dose for immunization. 
Although transglutaminase activity is present in 
small intestine, its role in the binding of  nitrofur- 
antoin metabolite to protein is uncertain. Reduc- 
tion of  the -NO2 group of  nitrofurantoin may lead 
to more than one reduction product, such as the 
-NH2 and - NHOH derivatives (Jonen et al., 1980). 
These derivatives are possible substrates of  trans- 
glutaminase. However, binding to protein of  5-ni- 
trofurans has been shown to occur with purified 
milk xanthine oxidase (Wang et al., 1974). Hence, 
transglutaminase activity is not essential to the 
binding. In our labeled experiments, we were also 
unable to demonstrate a significant lowering of  the 
binding with iodoacetamide. However, the low de- 
gree of  binding observed in the control experiments 
with inactivated tissue extract indicates that some 
kind of  enzymatic activity is required. In addition 
to enzymatic degradation of  nitrofurantoin, it is 
very likely that enzymatic activity is required for 
most of  the coupling with protein since none of  the 
known nitrofurontoin metabolites which could gen- 
erate antibodies reactive with 14C-nitrofurantoin is 
sufficiently reactive to couple covalently to protein 
without enzymatic intervention. 
Fig. 1 shows the antibody titer against nitrofur- 
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Fig. 1. Antibody formation in rabbits immunized with nitrofur- 
antoin metabolite-protein conjugate prepared from rat intestine 
extract. The ordinate shows the serum dilution required for 50% 
precipitation of labeled nitrofurantoin in a double antibody type 
radioimmunoassay. Initial immunization was with 50 #g bound 
nitrofurantoin in complete Freund's adjuvant, and the same an- 
tigen dose was injected one month later in incomplete Freund's 
adjuvant. 
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antoin in 2 rabbits immunized with protein conju- 
gate of  nitrofurantoin metabolite formed in rat 
small intestine extract. The highest titer (1:75-80) 
was obtained about 9-11 weeks after the initial in- 
jection. Control animals receiving free nitrofuran- 
toin in the same dosage as the experimental animals 
showed no antibody titer (data not shown). The 
successful demonstration of  the antihapten anti- 
body formation in these experiments implies that 
an extrahepatic tissue, such as small intestine, can 
metabolize an orally administered drug and con- 
jugate its metabolite(s) to protein. This conjugate 
may stimulate antibody formation against the drug 
hapten, thereby providing a mechanism for drug 
allergy. 
The fact that the drug hapten-protein conjuga- 
tion observed here appears to be enzymatically me- 
diated is worthy of  further comment. Detailed in- 
vestigations of  penicillin allergy have emphasized 
the generation of  reactive drug metabolites which 
can covalently bind to protein carriers. Accordingly 
it has been widely presumed that a similar mech- 
anism accounts for the development of  allergenicity 
to other drugs. However, in the 25 years since the 
mechanism of penicillin allergy was worked out 
(Parker et al., 1961; Levine and Ovary, 1961), there 
have been very few instances in which reactive 
metabolites have been found to account for im- 
munologically mediated reactions to other drugs. 
Thus, it is attractive to suggest that the binding to 
protein of  more stable drugs or drug metabolites by 
endogenous enzymes is a potential mechanism of  
drug allergy which merits consideration in studying 
reactions to other drugs. 
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